Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NYSE:RFL

Rafael Q2 2026 Earnings Report

Rafael logo
$1.27 0.00 (-0.16%)
Closing price 05/6/2026 03:58 PM Eastern
Extended Trading
$1.27 +0.00 (+0.16%)
As of 05/6/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Rafael EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Q2 2026
Date
3/16/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rafael's Q3 2026 earnings is estimated for Wednesday, June 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, June 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Rafael's Q2 2026 Press ReleasePress Release
(8-K)
Rafael's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Rafael Earnings Headlines

Rafael Holdings Insider Ups Holding By 1,810% During Year
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rafael-holdings-insider-ups-holding-142622929.html
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
April 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease-1036048049
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
 |  Brownstone Research (Ad)
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278798/0/en/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease.html
Rafael Holdings Inc. Wt
April 4, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfl.wt/company-people
Rafael Holdings, Inc.: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67960421-rafael-holdings-inc-rafael-holdings-reports-second-quarter-fiscal-2026-financial-results-399.htm
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile
Earnings Tools